Consequences of impressive myectomy results in a Center of Excellence: The paradox of evidence-based medicine era

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F20%3A10410842" target="_blank" >RIV/00216208:11130/20:10410842 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064203:_____/20:10410842

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=5ou_1TMUQ4" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=5ou_1TMUQ4</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.ahj.2019.12.009" target="_blank" >10.1016/j.ahj.2019.12.009</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Consequences of impressive myectomy results in a Center of Excellence: The paradox of evidence-based medicine era

Popis výsledku v původním jazyce

Two thirds of patients with hypertrophic obstructive cardiomyopathy (HOCM) suffer from left ventricular obstruction at rest and/or during exercise. These patients have a higher risk of heart failure and sudden cardiac death. Therefore, for symptomatic HOCM patients, a septal reduction therapy (surgical septal myectomy or alcohol septal ablation) is considered. In this issue of the American Heart Journal, the authors from the Mayo Clinic led by Dr Geske published an interesting long-term observation of HOCM patients treated with septal myectomy in their center between 2011 and 2014. The aim of the study was to report the outcome of septal myectomy in symptomatic HOCM patients at tertiary referral center and to evaluate if a risk score for these patients can be calculated by using the Society of Thoracic Surgeons Adult Cardiac Surgery Risk Calculator (STS Calculator) for outcomes of mitral valve repair and aortic valve replacement. The authors analyzed the outcomes of 298 carefully selected HOCM patients from a total of 676 septal myectomies performed at the Mayo Clinic and compared the observed results with a STS risk score for mitral valve repair and aortic valve replacement. They concluded there were no differences between observed mortality rates in patients undergoing septal myectomy and STS Calculator predicted risk for mitral valve repair and aortic valve replacement. Additionally, according to analyzed data, there was an impressive 0% early postmyectomy mortality rate and a 6-year survival rate of 98.7%.

Název v anglickém jazyce

Consequences of impressive myectomy results in a Center of Excellence: The paradox of evidence-based medicine era

Popis výsledku anglicky

Two thirds of patients with hypertrophic obstructive cardiomyopathy (HOCM) suffer from left ventricular obstruction at rest and/or during exercise. These patients have a higher risk of heart failure and sudden cardiac death. Therefore, for symptomatic HOCM patients, a septal reduction therapy (surgical septal myectomy or alcohol septal ablation) is considered. In this issue of the American Heart Journal, the authors from the Mayo Clinic led by Dr Geske published an interesting long-term observation of HOCM patients treated with septal myectomy in their center between 2011 and 2014. The aim of the study was to report the outcome of septal myectomy in symptomatic HOCM patients at tertiary referral center and to evaluate if a risk score for these patients can be calculated by using the Society of Thoracic Surgeons Adult Cardiac Surgery Risk Calculator (STS Calculator) for outcomes of mitral valve repair and aortic valve replacement. The authors analyzed the outcomes of 298 carefully selected HOCM patients from a total of 676 septal myectomies performed at the Mayo Clinic and compared the observed results with a STS risk score for mitral valve repair and aortic valve replacement. They concluded there were no differences between observed mortality rates in patients undergoing septal myectomy and STS Calculator predicted risk for mitral valve repair and aortic valve replacement. Additionally, according to analyzed data, there was an impressive 0% early postmyectomy mortality rate and a 6-year survival rate of 98.7%.

Druh

O - Ostatní výsledky

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2020

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů